Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway

Although cancer-associated fibroblast (CAF) heterogeneity is well-established, the impact of chemotherapy on CAF populations remains poorly understood. Here we address this question in high-grade serous ovarian cancer (HGSOC), in which we previously identified 4 CAF populations. While the global con...

Full description

Saved in:
Bibliographic Details
Published in:Nature communications Vol. 15; no. 1; pp. 1312 - 27
Main Authors: Licaj, Monika, Mhaidly, Rana, Kieffer, Yann, Croizer, Hugo, Bonneau, Claire, Meng, Arnaud, Djerroudi, Lounes, Mujangi-Ebeka, Kevin, Hocine, Hocine R., Bourachot, Brigitte, Magagna, Ilaria, Leclere, Renaud, Guyonnet, Lea, Bohec, Mylene, Guérin, Coralie, Baulande, Sylvain, Kamal, Maud, Le Tourneau, Christophe, Lecuru, Fabrice, Becette, Véronique, Rouzier, Roman, Vincent-Salomon, Anne, Gentric, Geraldine, Mechta-Grigoriou, Fatima
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 12.02.2024
Nature Publishing Group
Nature Portfolio
Subjects:
13
13/31
13/51
13/89
38
49
49/91
631/67/1517/1709
631/67/2329
692/4028/67/327
Cancer
Cancer therapies
CD8 antigen
Chemoresistance
Chemotherapy
Clusters
Cytotoxicity
Extracellular matrix
Fibroblasts
Heterogeneity
Humanities and Social Sciences
Immunity
Immunohistochemistry
Life Sciences
Lymphocytes
Lymphocytes T
multidisciplinary
Ovarian cancer
Populations
Science
Science (multidisciplinary)
Signal transduction
Spatial analysis
Stroma
Toxicity
Transcriptomics
Tumors
Yes-associated protein
ISSN:2041-1723, 2041-1723
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Although cancer-associated fibroblast (CAF) heterogeneity is well-established, the impact of chemotherapy on CAF populations remains poorly understood. Here we address this question in high-grade serous ovarian cancer (HGSOC), in which we previously identified 4 CAF populations. While the global content in stroma increases in HGSOC after chemotherapy, the proportion of FAP + CAF (also called CAF-S1) decreases. Still, maintenance of high residual CAF-S1 content after chemotherapy is associated with reduced CD8 + T lymphocyte density and poor patient prognosis, emphasizing the importance of CAF-S1 reduction upon treatment. Single cell analysis, spatial transcriptomics and immunohistochemistry reveal that the content in the ECM-producing ANTXR1 + CAF-S1 cluster (ECM-myCAF) is the most affected by chemotherapy. Moreover, functional assays demonstrate that ECM-myCAF isolated from HGSOC reduce CD8 + T-cell cytotoxicity through a Yes Associated Protein 1 (YAP1)-dependent mechanism. Thus, efficient inhibition after treatment of YAP1-signaling pathway in the ECM-myCAF cluster could enhance CD8 + T-cell cytotoxicity. Altogether, these data pave the way for therapy targeting YAP1 in ECM-myCAF in HGSOC. An important contribution of cancer associated fibroblasts (CAFs) in regulating chemoresistance has been reported. Here the authors investigate the impact of chemotherapy on CAF subsets in patients with high-grade serous ovarian cancer, suggesting that residual ANTXR1+ myofibroblasts are associated with inhibition of anti-tumor immunity.
AbstractList Abstract Although cancer-associated fibroblast (CAF) heterogeneity is well-established, the impact of chemotherapy on CAF populations remains poorly understood. Here we address this question in high-grade serous ovarian cancer (HGSOC), in which we previously identified 4 CAF populations. While the global content in stroma increases in HGSOC after chemotherapy, the proportion of FAP+ CAF (also called CAF-S1) decreases. Still, maintenance of high residual CAF-S1 content after chemotherapy is associated with reduced CD8+ T lymphocyte density and poor patient prognosis, emphasizing the importance of CAF-S1 reduction upon treatment. Single cell analysis, spatial transcriptomics and immunohistochemistry reveal that the content in the ECM-producing ANTXR1+ CAF-S1 cluster (ECM-myCAF) is the most affected by chemotherapy. Moreover, functional assays demonstrate that ECM-myCAF isolated from HGSOC reduce CD8+ T-cell cytotoxicity through a Yes Associated Protein 1 (YAP1)-dependent mechanism. Thus, efficient inhibition after treatment of YAP1-signaling pathway in the ECM-myCAF cluster could enhance CD8+ T-cell cytotoxicity. Altogether, these data pave the way for therapy targeting YAP1 in ECM-myCAF in HGSOC.
Although cancer-associated fibroblast (CAF) heterogeneity is well-established, the impact of chemotherapy on CAF populations remains poorly understood. Here we address this question in high-grade serous ovarian cancer (HGSOC), in which we previously identified 4 CAF populations. While the global content in stroma increases in HGSOC after chemotherapy, the proportion of FAP + CAF (also called CAF-S1) decreases. Still, maintenance of high residual CAF-S1 content after chemotherapy is associated with reduced CD8 + T lymphocyte density and poor patient prognosis, emphasizing the importance of CAF-S1 reduction upon treatment. Single cell analysis, spatial transcriptomics and immunohistochemistry reveal that the content in the ECM-producing ANTXR1 + CAF-S1 cluster (ECM-myCAF) is the most affected by chemotherapy. Moreover, functional assays demonstrate that ECM-myCAF isolated from HGSOC reduce CD8 + T-cell cytotoxicity through a Yes Associated Protein 1 (YAP1)-dependent mechanism. Thus, efficient inhibition after treatment of YAP1-signaling pathway in the ECM-myCAF cluster could enhance CD8 + T-cell cytotoxicity. Altogether, these data pave the way for therapy targeting YAP1 in ECM-myCAF in HGSOC.
Although cancer-associated fibroblast (CAF) heterogeneity is well-established, the impact of chemotherapy on CAF populations remains poorly understood. Here we address this question in high-grade serous ovarian cancer (HGSOC), in which we previously identified 4 CAF populations. While the global content in stroma increases in HGSOC after chemotherapy, the proportion of FAP+ CAF (also called CAF-S1) decreases. Still, maintenance of high residual CAF-S1 content after chemotherapy is associated with reduced CD8+ T lymphocyte density and poor patient prognosis, emphasizing the importance of CAF-S1 reduction upon treatment. Single cell analysis, spatial transcriptomics and immunohistochemistry reveal that the content in the ECM-producing ANTXR1+ CAF-S1 cluster (ECM-myCAF) is the most affected by chemotherapy. Moreover, functional assays demonstrate that ECM-myCAF isolated from HGSOC reduce CD8+ T-cell cytotoxicity through a Yes Associated Protein 1 (YAP1)-dependent mechanism. Thus, efficient inhibition after treatment of YAP1-signaling pathway in the ECM-myCAF cluster could enhance CD8+ T-cell cytotoxicity. Altogether, these data pave the way for therapy targeting YAP1 in ECM-myCAF in HGSOC.An important contribution of cancer associated fibroblasts (CAFs) in regulating chemoresistance has been reported. Here the authors investigate the impact of chemotherapy on CAF subsets in patients with high-grade serous ovarian cancer, suggesting that residual ANTXR1+ myofibroblasts are associated with inhibition of anti-tumor immunity.
Although cancer-associated fibroblast (CAF) heterogeneity is well-established, the impact of chemotherapy on CAF populations remains poorly understood. Here we address this question in high-grade serous ovarian cancer (HGSOC), in which we previously identified 4 CAF populations. While the global content in stroma increases in HGSOC after chemotherapy, the proportion of FAP + CAF (also called CAF-S1) decreases. Still, maintenance of high residual CAF-S1 content after chemotherapy is associated with reduced CD8 + T lymphocyte density and poor patient prognosis, emphasizing the importance of CAF-S1 reduction upon treatment. Single cell analysis, spatial transcriptomics and immunohistochemistry reveal that the content in the ECM-producing ANTXR1 + CAF-S1 cluster (ECM-myCAF) is the most affected by chemotherapy. Moreover, functional assays demonstrate that ECM-myCAF isolated from HGSOC reduce CD8 + T-cell cytotoxicity through a Yes Associated Protein 1 (YAP1)-dependent mechanism. Thus, efficient inhibition after treatment of YAP1-signaling pathway in the ECM-myCAF cluster could enhance CD8 + T-cell cytotoxicity. Altogether, these data pave the way for therapy targeting YAP1 in ECM-myCAF in HGSOC. An important contribution of cancer associated fibroblasts (CAFs) in regulating chemoresistance has been reported. Here the authors investigate the impact of chemotherapy on CAF subsets in patients with high-grade serous ovarian cancer, suggesting that residual ANTXR1+ myofibroblasts are associated with inhibition of anti-tumor immunity.
Although cancer-associated fibroblast (CAF) heterogeneity is well-established, the impact of chemotherapy on CAF populations remains poorly understood. Here we address this question in high-grade serous ovarian cancer (HGSOC), in which we previously identified 4 CAF populations. While the global content in stroma increases in HGSOC after chemotherapy, the proportion of FAP CAF (also called CAF-S1) decreases. Still, maintenance of high residual CAF-S1 content after chemotherapy is associated with reduced CD8 T lymphocyte density and poor patient prognosis, emphasizing the importance of CAF-S1 reduction upon treatment. Single cell analysis, spatial transcriptomics and immunohistochemistry reveal that the content in the ECM-producing ANTXR1 CAF-S1 cluster (ECM-myCAF) is the most affected by chemotherapy. Moreover, functional assays demonstrate that ECM-myCAF isolated from HGSOC reduce CD8 T-cell cytotoxicity through a Yes Associated Protein 1 (YAP1)-dependent mechanism. Thus, efficient inhibition after treatment of YAP1-signaling pathway in the ECM-myCAF cluster could enhance CD8 T-cell cytotoxicity. Altogether, these data pave the way for therapy targeting YAP1 in ECM-myCAF in HGSOC.
Although cancer-associated fibroblast (CAF) heterogeneity is well-established, the impact of chemotherapy on CAF populations remains poorly understood. Here we address this question in high-grade serous ovarian cancer (HGSOC), in which we previously identified 4 CAF populations. While the global content in stroma increases in HGSOC after chemotherapy, the proportion of FAP+ CAF (also called CAF-S1) decreases. Still, maintenance of high residual CAF-S1 content after chemotherapy is associated with reduced CD8+ T lymphocyte density and poor patient prognosis, emphasizing the importance of CAF-S1 reduction upon treatment. Single cell analysis, spatial transcriptomics and immunohistochemistry reveal that the content in the ECM-producing ANTXR1+ CAF-S1 cluster (ECM-myCAF) is the most affected by chemotherapy. Moreover, functional assays demonstrate that ECM-myCAF isolated from HGSOC reduce CD8+ T-cell cytotoxicity through a Yes Associated Protein 1 (YAP1)-dependent mechanism. Thus, efficient inhibition after treatment of YAP1-signaling pathway in the ECM-myCAF cluster could enhance CD8+ T-cell cytotoxicity. Altogether, these data pave the way for therapy targeting YAP1 in ECM-myCAF in HGSOC.Although cancer-associated fibroblast (CAF) heterogeneity is well-established, the impact of chemotherapy on CAF populations remains poorly understood. Here we address this question in high-grade serous ovarian cancer (HGSOC), in which we previously identified 4 CAF populations. While the global content in stroma increases in HGSOC after chemotherapy, the proportion of FAP+ CAF (also called CAF-S1) decreases. Still, maintenance of high residual CAF-S1 content after chemotherapy is associated with reduced CD8+ T lymphocyte density and poor patient prognosis, emphasizing the importance of CAF-S1 reduction upon treatment. Single cell analysis, spatial transcriptomics and immunohistochemistry reveal that the content in the ECM-producing ANTXR1+ CAF-S1 cluster (ECM-myCAF) is the most affected by chemotherapy. Moreover, functional assays demonstrate that ECM-myCAF isolated from HGSOC reduce CD8+ T-cell cytotoxicity through a Yes Associated Protein 1 (YAP1)-dependent mechanism. Thus, efficient inhibition after treatment of YAP1-signaling pathway in the ECM-myCAF cluster could enhance CD8+ T-cell cytotoxicity. Altogether, these data pave the way for therapy targeting YAP1 in ECM-myCAF in HGSOC.
ArticleNumber 1312
Author Mhaidly, Rana
Croizer, Hugo
Bourachot, Brigitte
Leclere, Renaud
Le Tourneau, Christophe
Guyonnet, Lea
Guérin, Coralie
Bonneau, Claire
Rouzier, Roman
Becette, Véronique
Bohec, Mylene
Hocine, Hocine R.
Vincent-Salomon, Anne
Kieffer, Yann
Magagna, Ilaria
Mechta-Grigoriou, Fatima
Djerroudi, Lounes
Meng, Arnaud
Baulande, Sylvain
Licaj, Monika
Lecuru, Fabrice
Mujangi-Ebeka, Kevin
Gentric, Geraldine
Kamal, Maud
Author_xml – sequence: 1
  givenname: Monika
  surname: Licaj
  fullname: Licaj, Monika
  organization: Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, PSL Research University, Inserm, U830
– sequence: 2
  givenname: Rana
  surname: Mhaidly
  fullname: Mhaidly, Rana
  organization: Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, PSL Research University, Inserm, U830
– sequence: 3
  givenname: Yann
  orcidid: 0000-0003-2722-3071
  surname: Kieffer
  fullname: Kieffer, Yann
  organization: Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, PSL Research University, Inserm, U830
– sequence: 4
  givenname: Hugo
  surname: Croizer
  fullname: Croizer, Hugo
  organization: Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, PSL Research University, Inserm, U830
– sequence: 5
  givenname: Claire
  orcidid: 0000-0001-6251-286X
  surname: Bonneau
  fullname: Bonneau, Claire
  organization: Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, PSL Research University, Inserm, U830, Department of Surgery, Institut Curie Hospital Group
– sequence: 6
  givenname: Arnaud
  surname: Meng
  fullname: Meng, Arnaud
  organization: Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, PSL Research University, Inserm, U830
– sequence: 7
  givenname: Lounes
  surname: Djerroudi
  fullname: Djerroudi, Lounes
  organization: Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, PSL Research University, Inserm, U830, Department of Diagnostic and Theragnostic Medicine, Institut Curie Hospital Group
– sequence: 8
  givenname: Kevin
  surname: Mujangi-Ebeka
  fullname: Mujangi-Ebeka, Kevin
  organization: Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, PSL Research University, Inserm, U830
– sequence: 9
  givenname: Hocine R.
  surname: Hocine
  fullname: Hocine, Hocine R.
  organization: Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, PSL Research University, Inserm, U830
– sequence: 10
  givenname: Brigitte
  orcidid: 0000-0001-7816-0539
  surname: Bourachot
  fullname: Bourachot, Brigitte
  organization: Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, PSL Research University, Inserm, U830
– sequence: 11
  givenname: Ilaria
  surname: Magagna
  fullname: Magagna, Ilaria
  organization: Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, PSL Research University, Inserm, U830
– sequence: 12
  givenname: Renaud
  surname: Leclere
  fullname: Leclere, Renaud
  organization: Department of Diagnostic and Theragnostic Medicine, Institut Curie Hospital Group
– sequence: 13
  givenname: Lea
  surname: Guyonnet
  fullname: Guyonnet, Lea
  organization: Cytometry platform, PSL University, Institut Curie
– sequence: 14
  givenname: Mylene
  orcidid: 0000-0002-6530-596X
  surname: Bohec
  fullname: Bohec, Mylene
  organization: ICGex Next-Generation Sequencing Platform, PSL University, Institut Curie
– sequence: 15
  givenname: Coralie
  orcidid: 0000-0002-1840-4017
  surname: Guérin
  fullname: Guérin, Coralie
  organization: Cytometry platform, PSL University, Institut Curie
– sequence: 16
  givenname: Sylvain
  orcidid: 0000-0003-3104-1684
  surname: Baulande
  fullname: Baulande, Sylvain
  organization: ICGex Next-Generation Sequencing Platform, PSL University, Institut Curie
– sequence: 17
  givenname: Maud
  surname: Kamal
  fullname: Kamal, Maud
  organization: Department of Drug Development and Innovation, Institut Curie Hospital Group
– sequence: 18
  givenname: Christophe
  orcidid: 0000-0001-9772-4686
  surname: Le Tourneau
  fullname: Le Tourneau, Christophe
  organization: Department of Drug Development and Innovation, Institut Curie Hospital Group, INSERM, U900, Paris-Saclay University, Institut Curie
– sequence: 19
  givenname: Fabrice
  surname: Lecuru
  fullname: Lecuru, Fabrice
  organization: Breast, gynecology and reconstructive surgery Department, Institut Curie Hospital Group, Paris Cité University
– sequence: 20
  givenname: Véronique
  surname: Becette
  fullname: Becette, Véronique
  organization: Department of Diagnostic and Theragnostic Medicine, Institut Curie Hospital Group
– sequence: 21
  givenname: Roman
  surname: Rouzier
  fullname: Rouzier, Roman
  organization: Department of Surgery, Institut Curie Hospital Group
– sequence: 22
  givenname: Anne
  orcidid: 0000-0001-5754-5771
  surname: Vincent-Salomon
  fullname: Vincent-Salomon, Anne
  organization: Department of Diagnostic and Theragnostic Medicine, Institut Curie Hospital Group
– sequence: 23
  givenname: Geraldine
  orcidid: 0000-0002-7558-8705
  surname: Gentric
  fullname: Gentric, Geraldine
  email: geraldine.gentric@curie.fr
  organization: Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, PSL Research University, Inserm, U830
– sequence: 24
  givenname: Fatima
  orcidid: 0000-0002-3751-6989
  surname: Mechta-Grigoriou
  fullname: Mechta-Grigoriou, Fatima
  email: fatima.mechta-grigoriou@curie.fr
  organization: Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, PSL Research University, Inserm, U830
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38346978$$D View this record in MEDLINE/PubMed
https://hal.science/hal-04547024$$DView record in HAL
BookMark eNp9Uk1v1DAUjFARLUv_AAcUiQsIBfyZjxNaVUArrQBVRYKTZTsvG6-SeLGdRfvvcTaltHuoL7bem5k3Gr_nyclgB0iSlxi9x4iWHzzDLC8yRFjGOK94Rp8kZwQxnOGC0JN779Pk3PsNiodWuGTsWXJKS8ryqijPEnMN3tSj7NLl15uf1_hd2u9tY5SzqpM--FQ2AVyqW-htaMHJ7T41Q2uUCakcgsnC2FuXmr4fBxP26c7I9NfyO069WQ-yM8M63crQ_pH7F8nTRnYezm_vRfLj86ebi8ts9e3L1cVylWle8JCpHDQiNcMVEAyNalBTaVbjmiiiFapQoWhBCVegq9iCgmnQdaVwDqqhlaaL5GrWra3ciK0zvXR7YaURh4J1ayFdMLoDwTUQznkMo8qZQlphrEiOJ3nQOaNR6-OstR1VD7WGITjZPRB92BlMK9Z2JzAqc8yj0UXydlZoj3iXy5WYaohxVsRf3OGIfXM7zdnfI_ggeuM1dJ0cwI5ekIrkqEQYkwh9fQTd2NHFwA8oTnHBWBlRr-7bv5v_7_sjgMwA7az3Dpo7CEZiWjMxr5mIBsVhzcQUSnlE0ibIYOwUgekep9KZ6uOcYQ3uv-1HWH8BUNbmRg
CitedBy_id crossref_primary_10_1016_j_trecan_2025_04_012
crossref_primary_10_1002_mco2_70292
crossref_primary_10_3390_biomedicines12091964
crossref_primary_10_1016_j_drup_2025_101273
crossref_primary_10_1016_j_jbc_2025_108330
crossref_primary_10_1038_s41467_025_62475_6
crossref_primary_10_3389_fimmu_2025_1635388
crossref_primary_10_1038_s41698_025_01066_6
crossref_primary_10_1007_s11010_025_05327_7
crossref_primary_10_1158_1078_0432_CCR_24_1690
crossref_primary_10_1158_0008_5472_CAN_24_3037
crossref_primary_10_1186_s13046_025_03527_z
crossref_primary_10_1002_mc_23719
crossref_primary_10_1016_j_mattod_2025_08_022
crossref_primary_10_1007_s00259_025_07126_0
crossref_primary_10_1111_cas_70133
Cites_doi 10.3390/cancers11010021
10.1097/IGC.0000000000001258
10.1093/jnci/dju249
10.1038/s41591-020-0926-0
10.18632/oncotarget.3828
10.1136/jcp.55.1.27
10.1016/j.semcancer.2022.04.008
10.7554/eLife.43803
10.1101/gr.240663.118
10.1016/j.coph.2016.05.002
10.1158/2159-8290.CD-19-0094
10.1038/s43018-022-00356-3
10.1038/nature25492
10.1038/s41588-021-00911-1
10.1080/2162402X.2022.2144669
10.1089/ars.2016.6750
10.1186/s13073-021-00922-x
10.1016/j.ccell.2020.01.003
10.1038/ncomms11762
10.1186/1471-2407-8-364
10.1016/S1470-2045(17)30469-2
10.1158/2159-8290.CD-19-1384
10.1016/j.ccr.2012.02.017
10.1038/srep26001
10.1371/journal.pone.0030269
10.1038/s41568-019-0238-1
10.1016/j.ccell.2018.01.011
10.1056/NEJMoa1810858
10.1001/jamaoncol.2017.3290
10.1016/j.ccell.2022.01.004
10.1073/pnas.1320318110
10.1016/j.canlet.2020.10.032
10.1152/physrev.00048.2019
10.1038/s41467-018-07987-0
10.1007/s00018-018-2954-1
10.1093/annonc/mdt556
10.1016/j.ccell.2016.05.005
10.1016/S0140-6736(17)32440-6
10.1016/j.ccell.2019.05.013
10.1016/j.ygyno.2018.10.008
10.1200/JCO.2002.20.5.1248
10.1038/s41598-017-08766-5
10.1016/j.ccell.2022.09.015
10.1038/srep16066
10.1038/nm.2512
10.3390/cancers12051307
10.1084/jem.20131195
10.1007/s13669-011-0004-1
10.1038/s41467-020-19408-2
10.1002/1878-0261.12905
10.3390/cancers13184720
10.3892/ijo.2011.906
10.1038/s41586-022-05496-1
10.1158/2326-6066.CIR-18-0098
10.1007/s00404-016-4035-8
10.1172/JCI87734
10.1074/mcp.M111.014647
10.1016/j.cmet.2018.08.007
10.1007/s00262-015-1742-0
10.1016/j.clon.2018.05.008
10.1038/s43018-020-0082-y
10.1093/annonc/mdx445
10.1158/0008-5472.CAN-17-1492
10.1158/0008-5472.CAN-14-3569
10.3389/fimmu.2022.923194
10.1016/j.ctrv.2018.12.002
10.18632/oncotarget.7818
10.1158/0008-5472.CAN-17-2320
10.1038/onc.2017.65
10.1016/j.smim.2020.101417
10.1038/ncomms10204
10.1038/s41592-021-01358-2
10.1101/gad.233676.113
10.1158/2159-8290.CD-17-1124
10.1038/nm.2890
10.1038/s43018-022-00411-z
10.1038/s41588-018-0179-8
10.3389/fgene.2020.00219
10.1016/j.ejca.2015.12.016
10.1016/j.ygyno.2020.11.026
10.3389/fonc.2022.1052132
10.1158/0008-5472.CAN-20-2116
10.1126/sciadv.abm1831
10.1038/ncomms9583
10.1038/s41586-022-05272-1
10.1038/nrc4019
10.3389/fimmu.2022.956224
10.1097/00000478-200402000-00009
10.1038/nm.4082
10.1016/S1470-2045(16)30559-9
10.1158/0008-5472.CAN-10-1242
10.1016/S1470-2045(17)30279-6
10.1016/j.ygyno.2015.09.011
10.1016/j.ygyno.2018.11.014
10.1038/s41588-019-0390-2
10.1084/jem.20162024
10.1158/0008-5472.CAN-15-2973
10.1038/ncomms9959
10.1186/s13046-020-1542-z
10.1593/tlo.12349
10.1016/j.cmet.2018.09.002
10.1158/2159-8290.CD-18-0710
10.1158/2159-8290.CD-19-0644
10.3390/cancers10080266
10.1016/j.trecan.2018.06.002
10.1016/j.cell.2016.04.009
10.1016/j.yexcr.2010.02.045
10.1002/emmm.201000073
10.3389/fimmu.2020.00580
10.1016/j.ccell.2018.06.008
10.1038/nmeth.2019
10.1002/path.5224
10.1186/s13048-019-0484-6
10.1038/s41467-018-07582-3
10.1158/1055-9965.EPI-18-1359
10.1073/pnas.1412910111
10.1186/s13058-017-0884-8
10.1186/s12916-015-0278-7
10.1038/nm.4078
10.18632/oncotarget.25126
10.1186/s13058-020-01311-9
10.1038/s41467-018-03348-z
10.1016/j.ccell.2022.01.005
10.1038/s41591-021-01323-8
10.1016/j.radonc.2015.05.007
10.1016/j.cell.2018.01.009
10.1056/NEJMoa1911361
10.1038/s41587-021-01139-4
10.3390/cells8121566
10.1038/s41598-017-17204-5
10.1038/s41467-022-33598-x
10.1038/s41467-019-14134-w
10.1038/nature10166
10.1038/nature25501
10.1016/j.cell.2021.09.022
10.1126/sciimmunol.abd5778
10.1016/j.ccell.2021.04.004
10.1038/ncb2756
10.1158/1078-0432.CCR-08-0196
10.1084/jem.20180765
10.1111/imr.12978
10.1038/s41588-020-0630-5
10.3390/ijms20092131
ContentType Journal Article
Copyright The Author(s) 2024
2024. The Author(s).
The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Distributed under a Creative Commons Attribution 4.0 International License
Copyright_xml – notice: The Author(s) 2024
– notice: 2024. The Author(s).
– notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Distributed under a Creative Commons Attribution 4.0 International License
DBID C6C
AAYXX
CITATION
NPM
3V.
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7X7
7XB
88E
8AO
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
ARAPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
P5Z
P62
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
RC3
SOI
7X8
1XC
5PM
DOA
DOI 10.1038/s41467-024-45595-3
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Ecology Abstracts
Entomology Abstracts (Full archive)
Environment Abstracts
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
One Sustainability
ProQuest Central UK/Ireland
Advanced Technologies & Computer Science Collection
ProQuest Central Essentials
Biological Science Collection
AUTh Library subscriptions: ProQuest Central
Technology Collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
Genetics Abstracts
Environment Abstracts
MEDLINE - Academic
Hyper Article en Ligne (HAL)
PubMed Central (Full Participant titles)
Open Access: DOAJ - Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
Chemoreception Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Advanced Technologies & Aerospace Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Entomology Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
AIDS and Cancer Research Abstracts
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Immunology Abstracts
Environment Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
CrossRef
Publicly Available Content Database

PubMed

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2041-1723
EndPage 27
ExternalDocumentID oai_doaj_org_article_5ce2555834964b0cb11b2617325ec643
PMC10861537
oai:HAL:hal-04547024v1
38346978
10_1038_s41467_024_45595_3
Genre Journal Article
GrantInformation_xml – fundername: Institut National Du Cancer (French National Cancer Institute)
  grantid: INCa-DGOS-9963; INCa-11692; INCa_16086; INCa_16101
  funderid: https://doi.org/10.13039/501100006364
– fundername: Institut National Du Cancer (French National Cancer Institute)
  grantid: INCa_16086
– fundername: Institut National Du Cancer (French National Cancer Institute)
  grantid: INCa-DGOS-9963
– fundername: Institut National Du Cancer (French National Cancer Institute)
  grantid: INCa-11692
– fundername: Institut National Du Cancer (French National Cancer Institute)
  grantid: INCa_16101
GroupedDBID ---
0R~
39C
3V.
53G
5VS
70F
7X7
88E
8AO
8FE
8FG
8FH
8FI
8FJ
AAHBH
AAJSJ
ABUWG
ACGFO
ACGFS
ACIWK
ACMJI
ACPRK
ACSMW
ADBBV
ADFRT
ADMLS
ADRAZ
AENEX
AEUYN
AFKRA
AFRAH
AHMBA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMTXH
AOIJS
ARAPS
ASPBG
AVWKF
AZFZN
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
EBLON
EBS
EE.
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
HCIFZ
HMCUK
HVGLF
HYE
HZ~
KQ8
LGEZI
LK8
LOTEE
M1P
M48
M7P
M~E
NADUK
NAO
NXXTH
O9-
OK1
P2P
P62
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RNT
RNTTT
RPM
SNYQT
SV3
TSG
UKHRP
AASML
AAYXX
AFFHD
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
NPM
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7XB
8FD
8FK
AZQEC
C1K
DWQXO
FR3
GNUQQ
H94
K9.
P64
PKEHL
PQEST
PQUKI
PRINS
RC3
SOI
7X8
1XC
5PM
ID FETCH-LOGICAL-c575t-b6ec02d419e21efbf0f9c4d1d2b2cb0907b37325bec90f9e74cecd9b16ebf39c3
IEDL.DBID DOA
ISICitedReferencesCount 24
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001161546900010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2041-1723
IngestDate Tue Oct 14 18:46:34 EDT 2025
Tue Nov 04 02:05:53 EST 2025
Tue Oct 14 20:36:59 EDT 2025
Sun Nov 09 12:38:16 EST 2025
Tue Oct 07 07:23:22 EDT 2025
Mon Jul 21 05:58:00 EDT 2025
Sat Nov 29 03:29:49 EST 2025
Tue Nov 18 22:00:45 EST 2025
Fri Feb 21 02:37:31 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2024. The Author(s).
Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c575t-b6ec02d419e21efbf0f9c4d1d2b2cb0907b37325bec90f9e74cecd9b16ebf39c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-3104-1684
0000-0002-6530-596X
0000-0001-6251-286X
0000-0002-1840-4017
0000-0001-5754-5771
0000-0002-3751-6989
0000-0002-7558-8705
0000-0003-2722-3071
0000-0001-9772-4686
0000-0001-7816-0539
0000-0002-0377-5077
OpenAccessLink https://doaj.org/article/5ce2555834964b0cb11b2617325ec643
PMID 38346978
PQID 2925317448
PQPubID 546298
PageCount 27
ParticipantIDs doaj_primary_oai_doaj_org_article_5ce2555834964b0cb11b2617325ec643
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10861537
hal_primary_oai_HAL_hal_04547024v1
proquest_miscellaneous_2926080112
proquest_journals_2925317448
pubmed_primary_38346978
crossref_primary_10_1038_s41467_024_45595_3
crossref_citationtrail_10_1038_s41467_024_45595_3
springer_journals_10_1038_s41467_024_45595_3
PublicationCentury 2000
PublicationDate 2024-02-12
PublicationDateYYYYMMDD 2024-02-12
PublicationDate_xml – month: 02
  year: 2024
  text: 2024-02-12
  day: 12
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Nature communications
PublicationTitleAbbrev Nat Commun
PublicationTitleAlternate Nat Commun
PublicationYear 2024
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Biffi, Tuveson (CR57) 2021; 101
Zanconato, Cordenonsi, Piccolo (CR135) 2016; 29
Kieffer (CR39) 2020; 11
Zanconato, Battilana, Cordenonsi, Piccolo (CR136) 2016; 29
Verset (CR118) 2015; 116
Sahai (CR55) 2020; 20
Zhang (CR31) 2015; 5
Zhang, Wang, Cliby (CR42) 2019; 152
Coleman (CR2) 2017; 18
Cohen (CR79) 2017; 36
Vienot (CR94) 2022; 11
Coleman (CR3) 2017; 390
Turcotte (CR62) 2015; 75
Albrengues (CR61) 2015; 6
Szelachowska (CR141) 2019; 18
Leca (CR63) 2016; 126
Li (CR123) 2021; 497
Woolston (CR119) 2019; 36
Mhaidly, Mechta-Grigoriou (CR84) 2021; 302
Costa (CR80) 2018; 33
Saigusa (CR114) 2011; 38
Laklai (CR130) 2016; 22
Mikula-Pietrasik (CR98) 2019; 76
Mariathasan (CR87) 2018; 554
Zhang, Chen, Fang, Luo (CR95) 2022; 12
Wu (CR58) 2021; 53
Lebid, Chung, Pardoll, Pan (CR139) 2020; 11
Kotliar (CR101) 2019; 8
Zhang (CR32) 2016; 6
Fang (CR34) 2018; 78
Ferrari (CR140) 2019; 10
Gulhan, Lee, Melloni, Cortes-Ciriano, Park (CR38) 2019; 51
Bristow, Tomacruz, Armstrong, Trimble, Montz (CR96) 2002; 20
Desbois (CR132) 2020; 11
Tothill (CR23) 2008; 14
Matondo (CR33) 2017; 7
Nwani, Sima, Nieves-Neira, Matei (CR91) 2018; 10
Macintyre (CR35) 2018; 50
Schindelin (CR148) 2012; 9
Denton, Roberts, Linterman, Fearon (CR74) 2014; 111
Shia (CR113) 2004; 28
Hu (CR41) 2020; 37
Pietras, Ostman (CR89) 2010; 316
Monteran (CR72) 2022; 13
Pujade-Lauraine (CR4) 2017; 18
Pelekanou (CR127) 2017; 19
Mhaidly, Mechta-Grigoriou (CR17) 2020; 48
Peltier, Seban, Buvat, Bidard, Mechta-Grigoriou (CR18) 2022; 86
Kleshchevnikov (CR103) 2022; 40
Schwede (CR44) 2020; 29
Sebastian (CR56) 2020; 12
Naba (CR150) 2012; 11
Gentric, Mieulet, Mechta-Grigoriou (CR13) 2017; 26
Cojocaru, Parkinson, Brenton (CR20) 2018; 30
Gao (CR65) 2019; 216
Han (CR66) 2019; 44
Sonnenberg (CR107) 2008; 8
Chen (CR134) 2014; 28
Ruhland (CR76) 2016; 7
Pozzi (CR125) 2016; 22
Palla (CR105) 2022; 19
Zou (CR73) 2022; 13
Eng, Hanlon, Bradley, Szender (CR97) 2015; 139
Zhang (CR22) 2019; 17
Bowtell (CR90) 2015; 15
Wang (CR126) 2016; 165
Curtis, Mukherjee, Lengyel (CR14) 2018; 4
Friedman (CR54) 2020; 1
Takahashi (CR75) 2015; 64
Krishnamurty (CR88) 2022; 611
Gueguen (CR149) 2021; 6
Asif, Longobardi, Hahne, Medema (CR70) 2021; 13
Cremasco (CR49) 2018; 6
Moore (CR6) 2018; 379
Batista, Bourachot, Mateescu, Reyal, Mechta-Grigoriou (CR30) 2016; 7
Lavie, Ben-Shmuel, Erez, Scherz-Shouval (CR85) 2022; 3
Dieci (CR124) 2014; 25
Feig (CR86) 2013; 110
Chu, Wang, Pe’er, Danko (CR102) 2022; 3
Olbrecht (CR45) 2021; 13
CR111
Bartoschek (CR48) 2018; 9
Calvo (CR133) 2013; 15
Gadducci (CR9) 2019; 12
Chen (CR11) 2015; 13
Stack, Nephew, Burdette, K Mitra (CR16) 2019; 11
Hall (CR137) 2010; 70
Biffi (CR50) 2019; 9
Menghi (CR36) 2018; 34
Coleridge (CR1) 2019; 2019
Wang, Xu, Zheng, Li (CR7) 2018; 28
Izar (CR43) 2020; 26
Dominguez (CR53) 2020; 10
Ghoneum, Afify, Salih, Kelly, Said (CR15) 2018; 9
Sun (CR116) 2012; 18
Gentric (CR37) 2019; 29
Foster (CR59) 2022; 40
Neuzillet (CR52) 2019; 248
Verhaak (CR27) 2013; 123
Tauriello (CR131) 2018; 554
Zhang, Ertl (CR78) 2016; 7
Maia (CR112) 2021; 15
Garcia-Alonso, Holland, Ibrahim, Turei, Saez-Rodriguez (CR104) 2019; 29
Yang (CR77) 2016; 76
Su (CR92) 2018; 172
Ni (CR138) 2018; 8
Gruosso (CR29) 2015; 6
Vazquez-Garcia (CR19) 2022; 612
Mateescu (CR25) 2011; 17
Hellevik (CR121) 2013; 6
Hansen, Coleman, Sood (CR12) 2016; 56
Bankhead (CR147) 2017; 7
Bonneau (CR67) 2020; 22
Nakasone (CR115) 2012; 21
Peiris-Pages, Sotgia, Lisanti (CR117) 2015; 6
Swisher (CR5) 2017; 18
(CR24) 2011; 474
Pelon (CR68) 2020; 11
Jimenez-Sanchez (CR128) 2020; 52
Givel (CR40) 2018; 9
Mhaidly, Mechta-Grigoriou (CR120) 2022; 40
Bentink (CR26) 2012; 7
(CR81) 2017; 3
Hinchcliff (CR21) 2018; 151
CR93
Grunwald (CR143) 2021; 184
Duska, Kohn (CR146) 2017; 28
Ohlund (CR47) 2017; 214
Meinhold-Heerlein (CR145) 2016; 293
Elyada (CR51) 2019; 9
Kieffer (CR82) 2020; 10
Shen (CR142) 2020; 39
Toullec (CR60) 2010; 2
Yue (CR71) 2021; 160
Curtis (CR64) 2019; 29
Ray-Coquard (CR10) 2019; 381
Shani (CR69) 2020; 80
Zhang (CR99) 2022; 8
Nicolas (CR110) 2022; 40
Dauer (CR129) 2018; 78
Kuhn, Kurman, Shih (CR144) 2012; 1
Franzese (CR8) 2019; 73
Deng (CR46) 2022; 13
Bassez (CR100) 2021; 27
Katayama (CR122) 2019; 8
McCluggage (CR106) 2002; 55
Hornburg (CR83) 2021; 39
Lotti (CR108) 2013; 210
Konecny (CR28) 2014; 106
CR109
T Chu (45595_CR102) 2022; 3
WG McCluggage (45595_CR106) 2002; 55
LR Duska (45595_CR146) 2017; 28
Q Zhang (45595_CR42) 2019; 152
DC Gulhan (45595_CR38) 2019; 51
G Biffi (45595_CR57) 2021; 101
H Yue (45595_CR71) 2021; 160
S Bentink (45595_CR26) 2012; 7
Z Hu (45595_CR41) 2020; 37
C Neuzillet (45595_CR52) 2019; 248
J Shia (45595_CR113) 2004; 28
MV Dieci (45595_CR124) 2014; 25
Y Li (45595_CR123) 2021; 497
J Szelachowska (45595_CR141) 2019; 18
X Yang (45595_CR77) 2016; 76
A Jimenez-Sanchez (45595_CR128) 2020; 52
G Zhang (45595_CR22) 2019; 17
A Vienot (45595_CR94) 2022; 11
H Laklai (45595_CR130) 2016; 22
P Bankhead (45595_CR147) 2017; 7
Y Kieffer (45595_CR39) 2020; 11
DD Bowtell (45595_CR90) 2015; 15
RL Coleman (45595_CR3) 2017; 390
T Gruosso (45595_CR29) 2015; 6
AM Nicolas (45595_CR110) 2022; 40
G Friedman (45595_CR54) 2020; 1
M Hornburg (45595_CR83) 2021; 39
SL Coleridge (45595_CR1) 2019; 2019
A Maia (45595_CR112) 2021; 15
L Verset (45595_CR118) 2015; 116
S Saigusa (45595_CR114) 2011; 38
I Vazquez-Garcia (45595_CR19) 2022; 612
ES Nakasone (45595_CR115) 2012; 21
Y Sun (45595_CR116) 2012; 18
C Pozzi (45595_CR125) 2016; 22
E Pujade-Lauraine (45595_CR4) 2017; 18
W Wang (45595_CR126) 2016; 165
K Moore (45595_CR6) 2018; 379
A Lebid (45595_CR139) 2020; 11
M Bartoschek (45595_CR48) 2018; 9
Q Gao (45595_CR65) 2019; 216
M Curtis (45595_CR14) 2018; 4
MS Stack (45595_CR16) 2019; 11
Y Zhang (45595_CR78) 2016; 7
V Kleshchevnikov (45595_CR103) 2022; 40
S Zhang (45595_CR31) 2015; 5
E Kuhn (45595_CR144) 2012; 1
Y Kieffer (45595_CR82) 2020; 10
L Garcia-Alonso (45595_CR104) 2019; 29
E Sahai (45595_CR55) 2020; 20
P Dauer (45595_CR129) 2018; 78
A Matondo (45595_CR33) 2017; 7
F Lotti (45595_CR108) 2013; 210
V Cremasco (45595_CR49) 2018; 6
DS Foster (45595_CR59) 2022; 40
CX Dominguez (45595_CR53) 2020; 10
A Sebastian (45595_CR56) 2020; 12
R Mhaidly (45595_CR84) 2021; 302
EM Swisher (45595_CR5) 2017; 18
L Monteran (45595_CR72) 2022; 13
B Mateescu (45595_CR25) 2011; 17
M Curtis (45595_CR64) 2019; 29
N Cohen (45595_CR79) 2017; 36
D Kotliar (45595_CR101) 2019; 8
T Shen (45595_CR142) 2020; 39
AM Givel (45595_CR40) 2018; 9
E Cojocaru (45595_CR20) 2018; 30
G Biffi (45595_CR50) 2019; 9
A Bassez (45595_CR100) 2021; 27
G Palla (45595_CR105) 2022; 19
H Wang (45595_CR7) 2018; 28
45595_CR93
Z Zhang (45595_CR32) 2016; 6
K Zhang (45595_CR99) 2022; 8
MLH Katayama (45595_CR122) 2019; 8
F Pelon (45595_CR68) 2020; 11
M Desbois (45595_CR132) 2020; 11
N Ferrari (45595_CR140) 2019; 10
J Albrengues (45595_CR61) 2015; 6
J Leca (45595_CR63) 2016; 126
V Pelekanou (45595_CR127) 2017; 19
R Mhaidly (45595_CR17) 2020; 48
45595_CR109
D Lavie (45595_CR85) 2022; 3
JM Hansen (45595_CR12) 2016; 56
G Macintyre (45595_CR35) 2018; 50
K Pietras (45595_CR89) 2010; 316
RE Bristow (45595_CR96) 2002; 20
R Mhaidly (45595_CR120) 2022; 40
J Zhang (45595_CR95) 2022; 12
S Mariathasan (45595_CR87) 2018; 554
L Batista (45595_CR30) 2016; 7
45595_CR111
A Woolston (45595_CR119) 2019; 36
A Toullec (45595_CR60) 2010; 2
G Gentric (45595_CR13) 2017; 26
RW Tothill (45595_CR23) 2008; 14
G Gentric (45595_CR37) 2019; 29
CA Hall (45595_CR137) 2010; 70
A Gadducci (45595_CR9) 2019; 12
C Feig (45595_CR86) 2013; 110
M Sonnenberg (45595_CR107) 2008; 8
A Naba (45595_CR150) 2012; 11
F Fang (45595_CR34) 2018; 78
RG Verhaak (45595_CR27) 2013; 123
Y Deng (45595_CR46) 2022; 13
F Zanconato (45595_CR135) 2016; 29
J Mikula-Pietrasik (45595_CR98) 2019; 76
D Ohlund (45595_CR47) 2017; 214
S Su (45595_CR92) 2018; 172
A Costa (45595_CR80) 2018; 33
M Peiris-Pages (45595_CR117) 2015; 6
P Gueguen (45595_CR149) 2021; 6
Q Han (45595_CR66) 2019; 44
AE Denton (45595_CR74) 2014; 111
PJ Asif (45595_CR70) 2021; 13
S Olbrecht (45595_CR45) 2021; 13
E Franzese (45595_CR8) 2019; 73
Cancer Genome Atlas Research N. (45595_CR24) 2011; 474
GE Konecny (45595_CR28) 2014; 106
Ovarian Tumor Tissue Analysis C. (45595_CR81) 2017; 3
H Takahashi (45595_CR75) 2015; 64
F Zanconato (45595_CR136) 2016; 29
F Menghi (45595_CR36) 2018; 34
T Hellevik (45595_CR121) 2013; 6
M Turcotte (45595_CR62) 2015; 75
I Ray-Coquard (45595_CR10) 2019; 381
DVF Tauriello (45595_CR131) 2018; 554
I Meinhold-Heerlein (45595_CR145) 2016; 293
F Calvo (45595_CR133) 2013; 15
SZ Wu (45595_CR58) 2021; 53
B Izar (45595_CR43) 2020; 26
O Shani (45595_CR69) 2020; 80
F Chen (45595_CR11) 2015; 13
A Ghoneum (45595_CR15) 2018; 9
E Elyada (45595_CR51) 2019; 9
X Ni (45595_CR138) 2018; 8
R Zou (45595_CR73) 2022; 13
MK Ruhland (45595_CR76) 2016; 7
AT Krishnamurty (45595_CR88) 2022; 611
A Peltier (45595_CR18) 2022; 86
J Schindelin (45595_CR148) 2012; 9
RL Coleman (45595_CR2) 2017; 18
C Bonneau (45595_CR67) 2020; 22
BT Grunwald (45595_CR143) 2021; 184
KH Eng (45595_CR97) 2015; 139
E Hinchcliff (45595_CR21) 2018; 151
NG Nwani (45595_CR91) 2018; 10
Q Chen (45595_CR134) 2014; 28
M Schwede (45595_CR44) 2020; 29
References_xml – volume: 11
  start-page: 21
  year: 2019
  ident: CR16
  article-title: The tumor microenvironment of high grade serous ovarian cancer
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers11010021
– volume: 28
  start-page: 903
  year: 2018
  end-page: 914
  ident: CR7
  article-title: Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials
  publication-title: Int. J. Gynecol. Cancer
  doi: 10.1097/IGC.0000000000001258
– volume: 106
  start-page: dju249
  year: 2014
  ident: CR28
  article-title: Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/dju249
– volume: 26
  start-page: 1271
  year: 2020
  end-page: 1279
  ident: CR43
  article-title: A single-cell landscape of high-grade serous ovarian cancer
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0926-0
– volume: 6
  start-page: 10728
  year: 2015
  end-page: 10745
  ident: CR117
  article-title: Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signalling in breast cancer cells
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.3828
– volume: 55
  start-page: 27
  year: 2002
  end-page: 31
  ident: CR106
  article-title: Morphological effects of chemotherapy on ovarian carcinoma
  publication-title: J. Clin. Pathol.
  doi: 10.1136/jcp.55.1.27
– volume: 86
  start-page: 262
  year: 2022
  end-page: 272
  ident: CR18
  article-title: Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2022.04.008
– volume: 8
  start-page: e43803
  year: 2019
  ident: CR101
  article-title: Identifying gene expression programs of cell-type identity and cellular activity with single-cell RNA-Seq
  publication-title: Elife
  doi: 10.7554/eLife.43803
– volume: 29
  start-page: 1363
  year: 2019
  end-page: 1375
  ident: CR104
  article-title: Benchmark and integration of resources for the estimation of human transcription factor activities
  publication-title: Genome Res.
  doi: 10.1101/gr.240663.118
– volume: 17
  start-page: 2583
  year: 2019
  end-page: 2591
  ident: CR22
  article-title: Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment
  publication-title: Oncol. Lett.
– volume: 29
  start-page: 26
  year: 2016
  end-page: 33
  ident: CR136
  article-title: YAP/TAZ as therapeutic targets in cancer
  publication-title: Curr. Opin. Pharm.
  doi: 10.1016/j.coph.2016.05.002
– volume: 9
  start-page: 1102
  year: 2019
  end-page: 1123
  ident: CR51
  article-title: Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-19-0094
– volume: 3
  start-page: 505
  year: 2022
  end-page: 517
  ident: CR102
  article-title: Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-022-00356-3
– volume: 554
  start-page: 538
  year: 2018
  end-page: 543
  ident: CR131
  article-title: TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
  publication-title: Nature
  doi: 10.1038/nature25492
– volume: 53
  start-page: 1334
  year: 2021
  end-page: 1347
  ident: CR58
  article-title: A single-cell and spatially resolved atlas of human breast cancers
  publication-title: Nat. Genet
  doi: 10.1038/s41588-021-00911-1
– volume: 11
  start-page: 2144669
  year: 2022
  ident: CR94
  article-title: Chemokine switch regulated by TGF-beta1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2022.2144669
– volume: 26
  start-page: 462
  year: 2017
  end-page: 485
  ident: CR13
  article-title: Heterogeneity in cancer metabolism: new concepts in an old field
  publication-title: Antioxid. Redox Signal
  doi: 10.1089/ars.2016.6750
– volume: 13
  year: 2021
  ident: CR45
  article-title: High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification
  publication-title: Genome Med.
  doi: 10.1186/s13073-021-00922-x
– volume: 37
  start-page: 226
  year: 2020
  end-page: 242 e227
  ident: CR41
  article-title: The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.01.003
– volume: 7
  year: 2016
  ident: CR76
  article-title: Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms11762
– volume: 8
  year: 2008
  ident: CR107
  article-title: Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-8-364
– volume: 18
  start-page: 1274
  year: 2017
  end-page: 1284
  ident: CR4
  article-title: Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30469-2
– volume: 10
  start-page: 1330
  year: 2020
  end-page: 1351
  ident: CR82
  article-title: Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-19-1384
– volume: 21
  start-page: 488
  year: 2012
  end-page: 503
  ident: CR115
  article-title: Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2012.02.017
– volume: 6
  year: 2016
  ident: CR32
  article-title: Molecular Subtyping of Serous Ovarian Cancer Based on Multi-omics Data
  publication-title: Sci. Rep.
  doi: 10.1038/srep26001
– volume: 7
  start-page: e30269
  year: 2012
  ident: CR26
  article-title: Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0030269
– volume: 20
  start-page: 174
  year: 2020
  end-page: 186
  ident: CR55
  article-title: A framework for advancing our understanding of cancer-associated fibroblasts
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-019-0238-1
– volume: 33
  start-page: 463
  year: 2018
  end-page: 479.e410
  ident: CR80
  article-title: Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.01.011
– volume: 379
  start-page: 2495
  year: 2018
  end-page: 2505
  ident: CR6
  article-title: Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1810858
– volume: 3
  start-page: e173290
  year: 2017
  ident: CR81
  article-title: Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2017.3290
– volume: 40
  start-page: 168
  year: 2022
  end-page: 184.e113
  ident: CR110
  article-title: Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2022.01.004
– volume: 110
  start-page: 20212
  year: 2013
  end-page: 20217
  ident: CR86
  article-title: Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
  publication-title: Proc. Natl Acad. Sci. USA.
  doi: 10.1073/pnas.1320318110
– volume: 497
  start-page: 212
  year: 2021
  end-page: 220
  ident: CR123
  article-title: Stress-induced upregulation of TNFSF4 in cancer-associated fibroblast facilitates chemoresistance of lung adenocarcinoma through inhibiting apoptosis of tumor cells
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2020.10.032
– volume: 101
  start-page: 147
  year: 2021
  end-page: 176
  ident: CR57
  article-title: Diversity and Biology of Cancer-Associated Fibroblasts
  publication-title: Physiol. Rev.
  doi: 10.1152/physrev.00048.2019
– volume: 10
  year: 2019
  ident: CR140
  article-title: Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-07987-0
– volume: 76
  start-page: 681
  year: 2019
  end-page: 697
  ident: CR98
  article-title: Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells
  publication-title: Cell Mol. Life Sci.
  doi: 10.1007/s00018-018-2954-1
– volume: 25
  start-page: 611
  year: 2014
  end-page: 618
  ident: CR124
  article-title: Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdt556
– volume: 29
  start-page: 783
  year: 2016
  end-page: 803
  ident: CR135
  article-title: YAP/TAZ at the Roots of Cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.05.005
– volume: 390
  start-page: 1949
  year: 2017
  end-page: 1961
  ident: CR3
  article-title: Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(17)32440-6
– ident: CR109
– volume: 36
  start-page: 35
  year: 2019
  end-page: 50.e39
  ident: CR119
  article-title: Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2019.05.013
– volume: 151
  start-page: 407
  year: 2018
  end-page: 413
  ident: CR21
  article-title: Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2018.10.008
– volume: 20
  start-page: 1248
  year: 2002
  end-page: 1259
  ident: CR96
  article-title: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2002.20.5.1248
– volume: 7
  year: 2017
  ident: CR33
  article-title: The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-08766-5
– volume: 40
  start-page: 1392
  year: 2022
  end-page: 1406 e1397
  ident: CR59
  article-title: Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2022.09.015
– volume: 5
  year: 2015
  ident: CR31
  article-title: Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer
  publication-title: Sci. Rep.
  doi: 10.1038/srep16066
– volume: 17
  start-page: 1627
  year: 2011
  end-page: 1635
  ident: CR25
  article-title: miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response
  publication-title: Nat. Med.
  doi: 10.1038/nm.2512
– volume: 12
  start-page: 1307
  year: 2020
  ident: CR56
  article-title: Single-Cell Transcriptomic Analysis of Tumor-Derived Fibroblasts and Normal Tissue-Resident Fibroblasts Reveals Fibroblast Heterogeneity in Breast Cancer
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12051307
– volume: 210
  start-page: 2851
  year: 2013
  end-page: 2872
  ident: CR108
  article-title: Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20131195
– volume: 1
  start-page: 1
  year: 2012
  end-page: 9
  ident: CR144
  article-title: Ovarian cancer is an imported disease: fact or fiction?
  publication-title: Curr. Obstet. Gynecol. Rep.
  doi: 10.1007/s13669-011-0004-1
– volume: 11
  year: 2020
  ident: CR132
  article-title: Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-19408-2
– volume: 15
  start-page: 1308
  year: 2021
  end-page: 1329
  ident: CR112
  article-title: IFNbeta1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment
  publication-title: Mol. Oncol.
  doi: 10.1002/1878-0261.12905
– volume: 13
  start-page: 4720
  year: 2021
  ident: CR70
  article-title: The Role of Cancer-Associated Fibroblasts in Cancer Invasion and Metastasis
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13184720
– volume: 38
  start-page: 655
  year: 2011
  end-page: 663
  ident: CR114
  article-title: Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy
  publication-title: Int J. Oncol.
  doi: 10.3892/ijo.2011.906
– volume: 612
  start-page: 778
  year: 2022
  end-page: 786
  ident: CR19
  article-title: Ovarian cancer mutational processes drive site-specific immune evasion
  publication-title: Nature
  doi: 10.1038/s41586-022-05496-1
– volume: 6
  start-page: 1472
  year: 2018
  end-page: 1485
  ident: CR49
  article-title: FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-18-0098
– volume: 293
  start-page: 695
  year: 2016
  end-page: 700
  ident: CR145
  article-title: The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications
  publication-title: Arch. Gynecol. Obstet.
  doi: 10.1007/s00404-016-4035-8
– volume: 126
  start-page: 4140
  year: 2016
  end-page: 4156
  ident: CR63
  article-title: Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI87734
– volume: 11
  start-page: M111 014647
  year: 2012
  ident: CR150
  article-title: The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices
  publication-title: Mol. Cell Proteom.
  doi: 10.1074/mcp.M111.014647
– volume: 29
  start-page: 141
  year: 2019
  end-page: 155.e149
  ident: CR64
  article-title: Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2018.08.007
– volume: 64
  start-page: 1407
  year: 2015
  end-page: 1417
  ident: CR75
  article-title: Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-015-1742-0
– volume: 30
  start-page: 515
  year: 2018
  end-page: 524
  ident: CR20
  article-title: Personalising Treatment for High-Grade Serous Ovarian Carcinoma
  publication-title: Clin. Oncol. (R. Coll. Radio.)
  doi: 10.1016/j.clon.2018.05.008
– volume: 1
  start-page: 692
  year: 2020
  end-page: 708
  ident: CR54
  article-title: Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4(+) and PDPN(+) CAFs to clinical outcome
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-020-0082-y
– volume: 28
  start-page: viii8
  year: 2017
  end-page: viii12
  ident: CR146
  article-title: The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdx445
– volume: 78
  start-page: 631
  year: 2018
  end-page: 644
  ident: CR34
  article-title: Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-1492
– volume: 75
  start-page: 4494
  year: 2015
  end-page: 4503
  ident: CR62
  article-title: CD73 is associated with poor prognosis in high-grade serous ovarian cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-14-3569
– volume: 13
  start-page: 923194
  year: 2022
  ident: CR46
  article-title: Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma
  publication-title: Front Immunol.
  doi: 10.3389/fimmu.2022.923194
– volume: 73
  start-page: 1
  year: 2019
  end-page: 9
  ident: CR8
  article-title: PARP inhibitors in ovarian cancer
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2018.12.002
– volume: 7
  start-page: 23282
  year: 2016
  end-page: 23299
  ident: CR78
  article-title: Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.7818
– volume: 78
  start-page: 1321
  year: 2018
  end-page: 1333
  ident: CR129
  article-title: Inactivation of cancer-associated-fibroblasts disrupts oncogenic signaling in pancreatic cancer cells and promotes its regression
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-2320
– volume: 36
  start-page: 4457
  year: 2017
  end-page: 4468
  ident: CR79
  article-title: Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1
  publication-title: Oncogene
  doi: 10.1038/onc.2017.65
– volume: 48
  start-page: 101417
  year: 2020
  ident: CR17
  article-title: Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies
  publication-title: Semin. Immunol.
  doi: 10.1016/j.smim.2020.101417
– volume: 6
  year: 2015
  ident: CR61
  article-title: Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms10204
– volume: 19
  start-page: 171
  year: 2022
  end-page: 178
  ident: CR105
  article-title: Squidpy: a scalable framework for spatial omics analysis
  publication-title: Nat. Methods
  doi: 10.1038/s41592-021-01358-2
– volume: 28
  start-page: 432
  year: 2014
  end-page: 437
  ident: CR134
  article-title: A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis
  publication-title: Genes Dev.
  doi: 10.1101/gad.233676.113
– volume: 8
  start-page: 1026
  year: 2018
  end-page: 1043
  ident: CR138
  article-title: YAP Is essential for treg-mediated suppression of antitumor immunity
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-17-1124
– volume: 18
  start-page: 1359
  year: 2012
  end-page: 1368
  ident: CR116
  article-title: Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B
  publication-title: Nat. Med.
  doi: 10.1038/nm.2890
– volume: 3
  start-page: 793
  year: 2022
  end-page: 807
  ident: CR85
  article-title: Cancer-associated fibroblasts in the single-cell era
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-022-00411-z
– volume: 50
  start-page: 1262
  year: 2018
  end-page: 1270
  ident: CR35
  article-title: Copy number signatures and mutational processes in ovarian carcinoma
  publication-title: Nat. Genet.
  doi: 10.1038/s41588-018-0179-8
– volume: 11
  start-page: 219
  year: 2020
  ident: CR39
  article-title: Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer
  publication-title: Front. Genet.
  doi: 10.3389/fgene.2020.00219
– volume: 56
  start-page: 131
  year: 2016
  end-page: 143
  ident: CR12
  article-title: Targeting the tumour microenvironment in ovarian cancer
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2015.12.016
– volume: 160
  start-page: 530
  year: 2021
  end-page: 538
  ident: CR71
  article-title: Stromal POSTN induced by TGF-beta1 facilitates the migration and invasion of ovarian cancer
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2020.11.026
– volume: 12
  start-page: 1052132
  year: 2022
  ident: CR95
  article-title: A cancer-associated fibroblast gene signature predicts prognosis and therapy response in patients with pancreatic cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.1052132
– volume: 80
  start-page: 5317
  year: 2020
  end-page: 5329
  ident: CR69
  article-title: Fibroblast-Derived IL33 Facilitates Breast Cancer Metastasis by Modifying the Immune Microenvironment and Driving Type 2 Immunity
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-20-2116
– ident: CR93
– volume: 8
  start-page: eabm1831
  year: 2022
  ident: CR99
  article-title: Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.abm1831
– volume: 6
  year: 2015
  ident: CR29
  article-title: MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms9583
– volume: 611
  start-page: 148
  year: 2022
  end-page: 154
  ident: CR88
  article-title: LRRC15(+) myofibroblasts dictate the stromal setpoint to suppress tumour immunity
  publication-title: Nature
  doi: 10.1038/s41586-022-05272-1
– volume: 18
  start-page: 3561
  year: 2019
  end-page: 3570
  ident: CR141
  article-title: The effect of YAP expression in tumor cells and tumor stroma on the prognosis of patients with squamous cell carcinoma of the oral cavity floor and oral surface of the tongue
  publication-title: Oncol. Lett.
– volume: 15
  start-page: 668
  year: 2015
  end-page: 679
  ident: CR90
  article-title: Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc4019
– volume: 44
  start-page: 2245
  year: 2019
  end-page: 2255
  ident: CR66
  article-title: Tumor cellfibroblast heterotypic aggregates in malignant ascites of patients with ovarian cancer
  publication-title: Int J. Mol. Med.
– volume: 13
  start-page: 956224
  year: 2022
  ident: CR73
  article-title: Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2022.956224
– ident: CR111
– volume: 28
  start-page: 215
  year: 2004
  end-page: 223
  ident: CR113
  article-title: Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome
  publication-title: Am. J. Surg. Pathol.
  doi: 10.1097/00000478-200402000-00009
– volume: 22
  start-page: 497
  year: 2016
  end-page: 505
  ident: CR130
  article-title: Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression
  publication-title: Nat. Med.
  doi: 10.1038/nm.4082
– volume: 123
  start-page: 517
  year: 2013
  end-page: 525
  ident: CR27
  article-title: Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
  publication-title: J. Clin. Invest.
– volume: 18
  start-page: 75
  year: 2017
  end-page: 87
  ident: CR5
  article-title: Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(16)30559-9
– volume: 70
  start-page: 8517
  year: 2010
  end-page: 8525
  ident: CR137
  article-title: Hippo pathway effector Yap is an ovarian cancer oncogene
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-10-1242
– volume: 18
  start-page: 779
  year: 2017
  end-page: 791
  ident: CR2
  article-title: Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30279-6
– volume: 139
  start-page: 228
  year: 2015
  end-page: 235
  ident: CR97
  article-title: Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2015.09.011
– volume: 152
  start-page: 368
  year: 2019
  end-page: 374
  ident: CR42
  article-title: Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2018.11.014
– volume: 51
  start-page: 912
  year: 2019
  end-page: 919
  ident: CR38
  article-title: Detecting the mutational signature of homologous recombination deficiency in clinical samples
  publication-title: Nat. Genet.
  doi: 10.1038/s41588-019-0390-2
– volume: 214
  start-page: 579
  year: 2017
  end-page: 596
  ident: CR47
  article-title: Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20162024
– volume: 2019
  start-page: CD005343
  year: 2019
  ident: CR1
  article-title: Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer
  publication-title: Cochrane Database Syst. Rev.
– volume: 76
  start-page: 4124
  year: 2016
  end-page: 4135
  ident: CR77
  article-title: FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-15-2973
– volume: 7
  start-page: 1
  year: 2016
  end-page: 17
  ident: CR30
  article-title: Regulation of miR-200c/141 expression by intergenic DNA-looping and transcriptional read-through
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms9959
– volume: 39
  start-page: 36
  year: 2020
  ident: CR142
  article-title: YAP1 plays a key role of the conversion of normal fibroblasts into cancer-associated fibroblasts that contribute to prostate cancer progression
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-020-1542-z
– volume: 6
  start-page: 66
  year: 2013
  end-page: 74
  ident: CR121
  article-title: Changes in the Secretory Profile of NSCLC-Associated Fibroblasts after Ablative Radiotherapy: Potential Impact on Angiogenesis and Tumor Growth
  publication-title: Transl. Oncol.
  doi: 10.1593/tlo.12349
– volume: 29
  start-page: 156
  year: 2019
  end-page: 173.e110
  ident: CR37
  article-title: PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2018.09.002
– volume: 9
  start-page: 282
  year: 2019
  end-page: 301
  ident: CR50
  article-title: IL1-Induced JAK/STAT Signaling Is Antagonized by TGFbeta to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-0710
– volume: 10
  start-page: 232
  year: 2020
  end-page: 253
  ident: CR53
  article-title: Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15(+) Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-19-0644
– volume: 10
  start-page: 266
  year: 2018
  ident: CR91
  article-title: Targeting the Microenvironment in High Grade Serous Ovarian Cancer
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers10080266
– volume: 4
  start-page: 517
  year: 2018
  end-page: 519
  ident: CR14
  article-title: The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2018.06.002
– volume: 165
  start-page: 1092
  year: 2016
  end-page: 1105
  ident: CR126
  article-title: Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer
  publication-title: Cell
  doi: 10.1016/j.cell.2016.04.009
– volume: 316
  start-page: 1324
  year: 2010
  end-page: 1331
  ident: CR89
  article-title: Hallmarks of cancer: interactions with the tumor stroma
  publication-title: Exp. Cell Res.
  doi: 10.1016/j.yexcr.2010.02.045
– volume: 2
  start-page: 211
  year: 2010
  end-page: 230
  ident: CR60
  article-title: Oxidative stress promotes myofibroblast differentiation and tumour spreading
  publication-title: EMBO Mol. Med.
  doi: 10.1002/emmm.201000073
– volume: 11
  start-page: 580
  year: 2020
  ident: CR139
  article-title: YAP Attenuates CD8 T cell-mediated anti-tumor response
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2020.00580
– volume: 34
  start-page: 197
  year: 2018
  end-page: 210.e195
  ident: CR36
  article-title: The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.06.008
– volume: 9
  start-page: 676
  year: 2012
  end-page: 682
  ident: CR148
  article-title: Fiji: an open-source platform for biological-image analysis
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.2019
– volume: 248
  start-page: 51
  year: 2019
  end-page: 65
  ident: CR52
  article-title: Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma
  publication-title: J. Pathol.
  doi: 10.1002/path.5224
– volume: 12
  year: 2019
  ident: CR9
  article-title: Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
  publication-title: J. Ovarian Res
  doi: 10.1186/s13048-019-0484-6
– volume: 9
  year: 2018
  ident: CR48
  article-title: Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single-cell RNA sequencing
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-07582-3
– volume: 29
  start-page: 509
  year: 2020
  end-page: 519
  ident: CR44
  article-title: The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer
  publication-title: Cancer Epidemiol. Biomark. Prev.
  doi: 10.1158/1055-9965.EPI-18-1359
– volume: 111
  start-page: 12139
  year: 2014
  end-page: 12144
  ident: CR74
  article-title: Fibroblastic reticular cells of the lymph node are required for retention of resting but not activated CD8+ T cells
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.1412910111
– volume: 19
  year: 2017
  ident: CR127
  article-title: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-017-0884-8
– volume: 13
  year: 2015
  ident: CR11
  article-title: New horizons in tumor microenvironment biology: challenges and opportunities
  publication-title: BMC Med.
  doi: 10.1186/s12916-015-0278-7
– volume: 22
  start-page: 624
  year: 2016
  end-page: 631
  ident: CR125
  article-title: The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
  publication-title: Nat. Med.
  doi: 10.1038/nm.4078
– volume: 9
  start-page: 22832
  year: 2018
  end-page: 22849
  ident: CR15
  article-title: Role of tumor microenvironment in ovarian cancer pathobiology
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.25126
– volume: 22
  year: 2020
  ident: CR67
  article-title: A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer
  publication-title: Breast Cancer Res.
  doi: 10.1186/s13058-020-01311-9
– volume: 9
  year: 2018
  ident: CR40
  article-title: miR200-regulated CXCL12beta promotes fibroblast heterogeneity and immunosuppression in ovarian cancers
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-03348-z
– volume: 40
  start-page: 122
  year: 2022
  end-page: 124
  ident: CR120
  article-title: Inflammatory fibroblasts make rectal cancer resistant to radiation therapy
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2022.01.005
– volume: 27
  start-page: 820
  year: 2021
  end-page: 832
  ident: CR100
  article-title: A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01323-8
– volume: 116
  start-page: 449
  year: 2015
  end-page: 454
  ident: CR118
  article-title: Impact of neoadjuvant therapy on cancer-associated fibroblasts in rectal cancer
  publication-title: Radiother. Oncol.
  doi: 10.1016/j.radonc.2015.05.007
– volume: 172
  start-page: 841
  year: 2018
  end-page: 856.e816
  ident: CR92
  article-title: CD10(+)GPR77(+) Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness
  publication-title: Cell
  doi: 10.1016/j.cell.2018.01.009
– volume: 381
  start-page: 2416
  year: 2019
  end-page: 2428
  ident: CR10
  article-title: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1911361
– volume: 40
  start-page: 661
  year: 2022
  end-page: 671
  ident: CR103
  article-title: Cell2location maps fine-grained cell types in spatial transcriptomics
  publication-title: Nat. Biotechnol.
  doi: 10.1038/s41587-021-01139-4
– volume: 8
  start-page: 1566
  year: 2019
  ident: CR122
  article-title: Stromal Cell Signature Associated with Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
  publication-title: Cells
  doi: 10.3390/cells8121566
– volume: 7
  year: 2017
  ident: CR147
  article-title: QuPath: Open source software for digital pathology image analysis
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-17204-5
– volume: 13
  year: 2022
  ident: CR72
  article-title: Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-33598-x
– volume: 11
  year: 2020
  ident: CR68
  article-title: Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-14134-w
– volume: 474
  start-page: 609
  year: 2011
  end-page: 615
  ident: CR24
  article-title: Integrated genomic analyses of ovarian carcinoma
  publication-title: Nature
  doi: 10.1038/nature10166
– volume: 554
  start-page: 544
  year: 2018
  end-page: 548
  ident: CR87
  article-title: TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
  publication-title: Nature
  doi: 10.1038/nature25501
– volume: 184
  start-page: 5577
  year: 2021
  end-page: 5592 e5518
  ident: CR143
  article-title: Spatially confined sub-tumor microenvironments in pancreatic cancer
  publication-title: Cell
  doi: 10.1016/j.cell.2021.09.022
– volume: 6
  start-page: eabd5778
  year: 2021
  ident: CR149
  article-title: Contribution of resident and circulating precursors to tumor-infiltrating CD8(+) T cell populations in lung cancer
  publication-title: Sci. Immunol.
  doi: 10.1126/sciimmunol.abd5778
– volume: 39
  start-page: 928
  year: 2021
  end-page: 944.e926
  ident: CR83
  article-title: Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.04.004
– volume: 15
  start-page: 637
  year: 2013
  end-page: 646
  ident: CR133
  article-title: Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts
  publication-title: Nat. Cell Biol.
  doi: 10.1038/ncb2756
– volume: 14
  start-page: 5198
  year: 2008
  end-page: 5208
  ident: CR23
  article-title: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-08-0196
– volume: 216
  start-page: 688
  year: 2019
  end-page: 703
  ident: CR65
  article-title: Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20180765
– volume: 302
  start-page: 259
  year: 2021
  end-page: 272
  ident: CR84
  article-title: Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12978
– volume: 52
  start-page: 582
  year: 2020
  end-page: 593
  ident: CR128
  article-title: Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy
  publication-title: Nat. Genet.
  doi: 10.1038/s41588-020-0630-5
– volume: 19
  start-page: 171
  year: 2022
  ident: 45595_CR105
  publication-title: Nat. Methods
  doi: 10.1038/s41592-021-01358-2
– volume: 316
  start-page: 1324
  year: 2010
  ident: 45595_CR89
  publication-title: Exp. Cell Res.
  doi: 10.1016/j.yexcr.2010.02.045
– volume: 76
  start-page: 681
  year: 2019
  ident: 45595_CR98
  publication-title: Cell Mol. Life Sci.
  doi: 10.1007/s00018-018-2954-1
– volume: 110
  start-page: 20212
  year: 2013
  ident: 45595_CR86
  publication-title: Proc. Natl Acad. Sci. USA.
  doi: 10.1073/pnas.1320318110
– volume: 165
  start-page: 1092
  year: 2016
  ident: 45595_CR126
  publication-title: Cell
  doi: 10.1016/j.cell.2016.04.009
– volume: 7
  year: 2017
  ident: 45595_CR147
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-17204-5
– volume: 381
  start-page: 2416
  year: 2019
  ident: 45595_CR10
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1911361
– volume: 28
  start-page: 215
  year: 2004
  ident: 45595_CR113
  publication-title: Am. J. Surg. Pathol.
  doi: 10.1097/00000478-200402000-00009
– volume: 55
  start-page: 27
  year: 2002
  ident: 45595_CR106
  publication-title: J. Clin. Pathol.
  doi: 10.1136/jcp.55.1.27
– volume: 11
  start-page: 21
  year: 2019
  ident: 45595_CR16
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers11010021
– volume: 3
  start-page: 505
  year: 2022
  ident: 45595_CR102
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-022-00356-3
– volume: 70
  start-page: 8517
  year: 2010
  ident: 45595_CR137
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-10-1242
– volume: 293
  start-page: 695
  year: 2016
  ident: 45595_CR145
  publication-title: Arch. Gynecol. Obstet.
  doi: 10.1007/s00404-016-4035-8
– volume: 20
  start-page: 1248
  year: 2002
  ident: 45595_CR96
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2002.20.5.1248
– volume: 13
  year: 2021
  ident: 45595_CR45
  publication-title: Genome Med.
  doi: 10.1186/s13073-021-00922-x
– volume: 9
  start-page: 282
  year: 2019
  ident: 45595_CR50
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-0710
– volume: 11
  year: 2020
  ident: 45595_CR132
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-19408-2
– volume: 50
  start-page: 1262
  year: 2018
  ident: 45595_CR35
  publication-title: Nat. Genet.
  doi: 10.1038/s41588-018-0179-8
– volume: 9
  start-page: 676
  year: 2012
  ident: 45595_CR148
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.2019
– volume: 5
  year: 2015
  ident: 45595_CR31
  publication-title: Sci. Rep.
  doi: 10.1038/srep16066
– volume: 40
  start-page: 1392
  year: 2022
  ident: 45595_CR59
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2022.09.015
– volume: 37
  start-page: 226
  year: 2020
  ident: 45595_CR41
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.01.003
– volume: 4
  start-page: 517
  year: 2018
  ident: 45595_CR14
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2018.06.002
– volume: 15
  start-page: 637
  year: 2013
  ident: 45595_CR133
  publication-title: Nat. Cell Biol.
  doi: 10.1038/ncb2756
– volume: 7
  start-page: 1
  year: 2016
  ident: 45595_CR30
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms9959
– volume: 214
  start-page: 579
  year: 2017
  ident: 45595_CR47
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20162024
– volume: 33
  start-page: 463
  year: 2018
  ident: 45595_CR80
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.01.011
– volume: 7
  start-page: 23282
  year: 2016
  ident: 45595_CR78
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.7818
– volume: 29
  start-page: 783
  year: 2016
  ident: 45595_CR135
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.05.005
– volume: 20
  start-page: 174
  year: 2020
  ident: 45595_CR55
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-019-0238-1
– volume: 554
  start-page: 544
  year: 2018
  ident: 45595_CR87
  publication-title: Nature
  doi: 10.1038/nature25501
– volume: 21
  start-page: 488
  year: 2012
  ident: 45595_CR115
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2012.02.017
– volume: 56
  start-page: 131
  year: 2016
  ident: 45595_CR12
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2015.12.016
– volume: 2019
  start-page: CD005343
  year: 2019
  ident: 45595_CR1
  publication-title: Cochrane Database Syst. Rev.
– volume: 11
  start-page: 219
  year: 2020
  ident: 45595_CR39
  publication-title: Front. Genet.
  doi: 10.3389/fgene.2020.00219
– volume: 139
  start-page: 228
  year: 2015
  ident: 45595_CR97
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2015.09.011
– volume: 22
  year: 2020
  ident: 45595_CR67
  publication-title: Breast Cancer Res.
  doi: 10.1186/s13058-020-01311-9
– volume: 64
  start-page: 1407
  year: 2015
  ident: 45595_CR75
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-015-1742-0
– ident: 45595_CR111
– volume: 18
  start-page: 3561
  year: 2019
  ident: 45595_CR141
  publication-title: Oncol. Lett.
– volume: 75
  start-page: 4494
  year: 2015
  ident: 45595_CR62
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-14-3569
– volume: 10
  start-page: 266
  year: 2018
  ident: 45595_CR91
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers10080266
– volume: 15
  start-page: 1308
  year: 2021
  ident: 45595_CR112
  publication-title: Mol. Oncol.
  doi: 10.1002/1878-0261.12905
– volume: 8
  year: 2008
  ident: 45595_CR107
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-8-364
– volume: 13
  year: 2022
  ident: 45595_CR72
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-33598-x
– volume: 10
  start-page: 232
  year: 2020
  ident: 45595_CR53
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-19-0644
– volume: 25
  start-page: 611
  year: 2014
  ident: 45595_CR124
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdt556
– volume: 111
  start-page: 12139
  year: 2014
  ident: 45595_CR74
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.1412910111
– volume: 30
  start-page: 515
  year: 2018
  ident: 45595_CR20
  publication-title: Clin. Oncol. (R. Coll. Radio.)
  doi: 10.1016/j.clon.2018.05.008
– volume: 8
  start-page: 1566
  year: 2019
  ident: 45595_CR122
  publication-title: Cells
  doi: 10.3390/cells8121566
– volume: 611
  start-page: 148
  year: 2022
  ident: 45595_CR88
  publication-title: Nature
  doi: 10.1038/s41586-022-05272-1
– volume: 6
  year: 2015
  ident: 45595_CR29
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms9583
– volume: 29
  start-page: 156
  year: 2019
  ident: 45595_CR37
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2018.09.002
– volume: 29
  start-page: 1363
  year: 2019
  ident: 45595_CR104
  publication-title: Genome Res.
  doi: 10.1101/gr.240663.118
– volume: 1
  start-page: 692
  year: 2020
  ident: 45595_CR54
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-020-0082-y
– volume: 6
  start-page: 10728
  year: 2015
  ident: 45595_CR117
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.3828
– volume: 379
  start-page: 2495
  year: 2018
  ident: 45595_CR6
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1810858
– volume: 22
  start-page: 624
  year: 2016
  ident: 45595_CR125
  publication-title: Nat. Med.
  doi: 10.1038/nm.4078
– volume: 34
  start-page: 197
  year: 2018
  ident: 45595_CR36
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.06.008
– volume: 13
  start-page: 923194
  year: 2022
  ident: 45595_CR46
  publication-title: Front Immunol.
  doi: 10.3389/fimmu.2022.923194
– volume: 8
  start-page: 1026
  year: 2018
  ident: 45595_CR138
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-17-1124
– volume: 18
  start-page: 779
  year: 2017
  ident: 45595_CR2
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30279-6
– volume: 497
  start-page: 212
  year: 2021
  ident: 45595_CR123
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2020.10.032
– volume: 14
  start-page: 5198
  year: 2008
  ident: 45595_CR23
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-08-0196
– volume: 172
  start-page: 841
  year: 2018
  ident: 45595_CR92
  publication-title: Cell
  doi: 10.1016/j.cell.2018.01.009
– volume: 18
  start-page: 75
  year: 2017
  ident: 45595_CR5
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(16)30559-9
– volume: 29
  start-page: 141
  year: 2019
  ident: 45595_CR64
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2018.08.007
– volume: 19
  year: 2017
  ident: 45595_CR127
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-017-0884-8
– volume: 210
  start-page: 2851
  year: 2013
  ident: 45595_CR108
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20131195
– volume: 17
  start-page: 2583
  year: 2019
  ident: 45595_CR22
  publication-title: Oncol. Lett.
– volume: 7
  start-page: e30269
  year: 2012
  ident: 45595_CR26
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0030269
– volume: 184
  start-page: 5577
  year: 2021
  ident: 45595_CR143
  publication-title: Cell
  doi: 10.1016/j.cell.2021.09.022
– volume: 9
  start-page: 1102
  year: 2019
  ident: 45595_CR51
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-19-0094
– volume: 40
  start-page: 168
  year: 2022
  ident: 45595_CR110
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2022.01.004
– volume: 612
  start-page: 778
  year: 2022
  ident: 45595_CR19
  publication-title: Nature
  doi: 10.1038/s41586-022-05496-1
– volume: 474
  start-page: 609
  year: 2011
  ident: 45595_CR24
  publication-title: Nature
  doi: 10.1038/nature10166
– volume: 15
  start-page: 668
  year: 2015
  ident: 45595_CR90
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc4019
– volume: 116
  start-page: 449
  year: 2015
  ident: 45595_CR118
  publication-title: Radiother. Oncol.
  doi: 10.1016/j.radonc.2015.05.007
– volume: 160
  start-page: 530
  year: 2021
  ident: 45595_CR71
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2020.11.026
– volume: 12
  start-page: 1307
  year: 2020
  ident: 45595_CR56
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12051307
– volume: 78
  start-page: 631
  year: 2018
  ident: 45595_CR34
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-1492
– volume: 44
  start-page: 2245
  year: 2019
  ident: 45595_CR66
  publication-title: Int J. Mol. Med.
– volume: 8
  start-page: e43803
  year: 2019
  ident: 45595_CR101
  publication-title: Elife
  doi: 10.7554/eLife.43803
– volume: 36
  start-page: 4457
  year: 2017
  ident: 45595_CR79
  publication-title: Oncogene
  doi: 10.1038/onc.2017.65
– volume: 22
  start-page: 497
  year: 2016
  ident: 45595_CR130
  publication-title: Nat. Med.
  doi: 10.1038/nm.4082
– volume: 13
  year: 2015
  ident: 45595_CR11
  publication-title: BMC Med.
  doi: 10.1186/s12916-015-0278-7
– volume: 123
  start-page: 517
  year: 2013
  ident: 45595_CR27
  publication-title: J. Clin. Invest.
– volume: 12
  start-page: 1052132
  year: 2022
  ident: 45595_CR95
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.1052132
– volume: 26
  start-page: 1271
  year: 2020
  ident: 45595_CR43
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0926-0
– volume: 6
  year: 2016
  ident: 45595_CR32
  publication-title: Sci. Rep.
  doi: 10.1038/srep26001
– volume: 11
  start-page: 580
  year: 2020
  ident: 45595_CR139
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2020.00580
– volume: 11
  start-page: 2144669
  year: 2022
  ident: 45595_CR94
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2022.2144669
– volume: 216
  start-page: 688
  year: 2019
  ident: 45595_CR65
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20180765
– volume: 13
  start-page: 956224
  year: 2022
  ident: 45595_CR73
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2022.956224
– volume: 6
  start-page: eabd5778
  year: 2021
  ident: 45595_CR149
  publication-title: Sci. Immunol.
  doi: 10.1126/sciimmunol.abd5778
– volume: 53
  start-page: 1334
  year: 2021
  ident: 45595_CR58
  publication-title: Nat. Genet
  doi: 10.1038/s41588-021-00911-1
– volume: 40
  start-page: 661
  year: 2022
  ident: 45595_CR103
  publication-title: Nat. Biotechnol.
  doi: 10.1038/s41587-021-01139-4
– volume: 152
  start-page: 368
  year: 2019
  ident: 45595_CR42
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2018.11.014
– volume: 101
  start-page: 147
  year: 2021
  ident: 45595_CR57
  publication-title: Physiol. Rev.
  doi: 10.1152/physrev.00048.2019
– volume: 3
  start-page: e173290
  year: 2017
  ident: 45595_CR81
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2017.3290
– volume: 40
  start-page: 122
  year: 2022
  ident: 45595_CR120
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2022.01.005
– volume: 73
  start-page: 1
  year: 2019
  ident: 45595_CR8
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2018.12.002
– volume: 9
  year: 2018
  ident: 45595_CR40
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-03348-z
– volume: 52
  start-page: 582
  year: 2020
  ident: 45595_CR128
  publication-title: Nat. Genet.
  doi: 10.1038/s41588-020-0630-5
– volume: 9
  year: 2018
  ident: 45595_CR48
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-07582-3
– volume: 8
  start-page: eabm1831
  year: 2022
  ident: 45595_CR99
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.abm1831
– volume: 86
  start-page: 262
  year: 2022
  ident: 45595_CR18
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2022.04.008
– volume: 10
  year: 2019
  ident: 45595_CR140
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-07987-0
– volume: 7
  year: 2017
  ident: 45595_CR33
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-08766-5
– volume: 29
  start-page: 509
  year: 2020
  ident: 45595_CR44
  publication-title: Cancer Epidemiol. Biomark. Prev.
  doi: 10.1158/1055-9965.EPI-18-1359
– volume: 106
  start-page: dju249
  year: 2014
  ident: 45595_CR28
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/dju249
– volume: 27
  start-page: 820
  year: 2021
  ident: 45595_CR100
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01323-8
– volume: 6
  start-page: 66
  year: 2013
  ident: 45595_CR121
  publication-title: Transl. Oncol.
  doi: 10.1593/tlo.12349
– volume: 1
  start-page: 1
  year: 2012
  ident: 45595_CR144
  publication-title: Curr. Obstet. Gynecol. Rep.
  doi: 10.1007/s13669-011-0004-1
– ident: 45595_CR109
– volume: 39
  start-page: 36
  year: 2020
  ident: 45595_CR142
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-020-1542-z
– volume: 28
  start-page: 432
  year: 2014
  ident: 45595_CR134
  publication-title: Genes Dev.
  doi: 10.1101/gad.233676.113
– volume: 6
  start-page: 1472
  year: 2018
  ident: 45595_CR49
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-18-0098
– ident: 45595_CR93
  doi: 10.3390/ijms20092131
– volume: 6
  year: 2015
  ident: 45595_CR61
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms10204
– volume: 39
  start-page: 928
  year: 2021
  ident: 45595_CR83
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.04.004
– volume: 12
  year: 2019
  ident: 45595_CR9
  publication-title: J. Ovarian Res
  doi: 10.1186/s13048-019-0484-6
– volume: 7
  year: 2016
  ident: 45595_CR76
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms11762
– volume: 80
  start-page: 5317
  year: 2020
  ident: 45595_CR69
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-20-2116
– volume: 28
  start-page: 903
  year: 2018
  ident: 45595_CR7
  publication-title: Int. J. Gynecol. Cancer
  doi: 10.1097/IGC.0000000000001258
– volume: 26
  start-page: 462
  year: 2017
  ident: 45595_CR13
  publication-title: Antioxid. Redox Signal
  doi: 10.1089/ars.2016.6750
– volume: 302
  start-page: 259
  year: 2021
  ident: 45595_CR84
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12978
– volume: 151
  start-page: 407
  year: 2018
  ident: 45595_CR21
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2018.10.008
– volume: 17
  start-page: 1627
  year: 2011
  ident: 45595_CR25
  publication-title: Nat. Med.
  doi: 10.1038/nm.2512
– volume: 11
  start-page: M111 014647
  year: 2012
  ident: 45595_CR150
  publication-title: Mol. Cell Proteom.
  doi: 10.1074/mcp.M111.014647
– volume: 18
  start-page: 1274
  year: 2017
  ident: 45595_CR4
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30469-2
– volume: 2
  start-page: 211
  year: 2010
  ident: 45595_CR60
  publication-title: EMBO Mol. Med.
  doi: 10.1002/emmm.201000073
– volume: 13
  start-page: 4720
  year: 2021
  ident: 45595_CR70
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13184720
– volume: 390
  start-page: 1949
  year: 2017
  ident: 45595_CR3
  publication-title: Lancet
  doi: 10.1016/S0140-6736(17)32440-6
– volume: 3
  start-page: 793
  year: 2022
  ident: 45595_CR85
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-022-00411-z
– volume: 78
  start-page: 1321
  year: 2018
  ident: 45595_CR129
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-2320
– volume: 126
  start-page: 4140
  year: 2016
  ident: 45595_CR63
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI87734
– volume: 10
  start-page: 1330
  year: 2020
  ident: 45595_CR82
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-19-1384
– volume: 18
  start-page: 1359
  year: 2012
  ident: 45595_CR116
  publication-title: Nat. Med.
  doi: 10.1038/nm.2890
– volume: 28
  start-page: viii8
  year: 2017
  ident: 45595_CR146
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdx445
– volume: 11
  year: 2020
  ident: 45595_CR68
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-14134-w
– volume: 48
  start-page: 101417
  year: 2020
  ident: 45595_CR17
  publication-title: Semin. Immunol.
  doi: 10.1016/j.smim.2020.101417
– volume: 36
  start-page: 35
  year: 2019
  ident: 45595_CR119
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2019.05.013
– volume: 76
  start-page: 4124
  year: 2016
  ident: 45595_CR77
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-15-2973
– volume: 9
  start-page: 22832
  year: 2018
  ident: 45595_CR15
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.25126
– volume: 51
  start-page: 912
  year: 2019
  ident: 45595_CR38
  publication-title: Nat. Genet.
  doi: 10.1038/s41588-019-0390-2
– volume: 554
  start-page: 538
  year: 2018
  ident: 45595_CR131
  publication-title: Nature
  doi: 10.1038/nature25492
– volume: 29
  start-page: 26
  year: 2016
  ident: 45595_CR136
  publication-title: Curr. Opin. Pharm.
  doi: 10.1016/j.coph.2016.05.002
– volume: 38
  start-page: 655
  year: 2011
  ident: 45595_CR114
  publication-title: Int J. Oncol.
  doi: 10.3892/ijo.2011.906
– volume: 248
  start-page: 51
  year: 2019
  ident: 45595_CR52
  publication-title: J. Pathol.
  doi: 10.1002/path.5224
SSID ssj0000391844
Score 2.5412285
Snippet Although cancer-associated fibroblast (CAF) heterogeneity is well-established, the impact of chemotherapy on CAF populations remains poorly understood. Here we...
Abstract Although cancer-associated fibroblast (CAF) heterogeneity is well-established, the impact of chemotherapy on CAF populations remains poorly...
SourceID doaj
pubmedcentral
hal
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1312
SubjectTerms 13
13/31
13/51
13/89
38
49
49/91
631/67/1517/1709
631/67/2329
692/4028/67/327
Cancer
Cancer therapies
CD8 antigen
Chemoresistance
Chemotherapy
Clusters
Cytotoxicity
Extracellular matrix
Fibroblasts
Heterogeneity
Humanities and Social Sciences
Immunity
Immunohistochemistry
Life Sciences
Lymphocytes
Lymphocytes T
multidisciplinary
Ovarian cancer
Populations
Science
Science (multidisciplinary)
Signal transduction
Spatial analysis
Stroma
Toxicity
Transcriptomics
Tumors
Yes-associated protein
SummonAdditionalLinks – databaseName: Biological Science Database
  dbid: M7P
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwELWggMSFb2igIIO4FauJ43yd0IKoeqhWq6qg5WTZjtONxCbtJrso_54ZJ5tqqeiFa-wkdubZntgz7xHyUYkojVUuWBTGgonEGpbmRjFfOXIZkcQui__HaTKdpvN5Nhs23JohrHI7J7qJOq8N7pEf8YwDXBL4m_h8ecVQNQpPVwcJjbvkHrIkcBe6Nxv3WJD9PBViyJXxw_SoEW5mgIWJCfClIxburEeOth9WmQUGRd70OG8GTv51euoWpePH_9udJ-TR4I7SSY-fp-SOrZ6RB71AZfeclGe2cdladDI9n58Fh3TZARo1qtCopm2okxinYPjlkMnV0bJalLpsKZisZO16Wa9o6ZJQ2o5uSkV_TmYBxbARhZnwFCWRf6vuBfl-_O386wkbxBmYAQ-vZTq2xue5CDLLA1vowi8yI_Ig55ob7cM_tw6TkEeAkQyKbCKMNXmmg9jqIsxM-JLsVXVl9wktMqVyPy244UroCDwknRYFzws_LkzuRx4JtiaSZmAuRwGNX9KdoIep7M0qwazSmVWGHjkc77nseTturf0FLT_WRM5td6FeXchhCMvIWI7saEixL7RvdBBo5LOHTloDjp1HPgBudp5xMjmVeA15DhN43ybwyMEWD3KYLRp5DQaPvB-LYZzj4Y2qbL12dWLw7sE99sirHoXjq0JoU5wlcHe6g8-dtuyWVOXCcYmj0BYseolHPm2hfN2uf3-w17d34w15yHGMOeGcA7LXrtb2LblvNm3ZrN65QfoH55RDQw
  priority: 102
  providerName: ProQuest
Title Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway
URI https://link.springer.com/article/10.1038/s41467-024-45595-3
https://www.ncbi.nlm.nih.gov/pubmed/38346978
https://www.proquest.com/docview/2925317448
https://www.proquest.com/docview/2926080112
https://hal.science/hal-04547024
https://pubmed.ncbi.nlm.nih.gov/PMC10861537
https://doaj.org/article/5ce2555834964b0cb11b2617325ec643
Volume 15
WOSCitedRecordID wos001161546900010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: DOA
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: M~E
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: M7P
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: 7X7
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest advanced technologies & aerospace journals
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: P5Z
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/hightechjournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: BENPR
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: PIMPY
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED_BAIkXxDeBURnE24iW2M7XY4c2DWlUUTVQx4tlO44aiaaoSYvy33N20rIyAS-85CF2G-vu7LuT734_gHeSR2ksC-5HLOY-T4z200JLP5AOXIYnsevi_3KRTCbpbJbl16i-bE1YDw_cC-440oZaTCoLbM5VoFUYKosizmhkNLpTe_oGSXYtmXJnMMswdeFDl0zA0uOGuzMBXZLPMYqOfLbniRxgP_qXuS2HvBlr3iyZ_O3e1Lmjs4fwYIgjybhf_yO4ZerHcK9nluyeQDU1jWuzIuPJ5WwaHpFFh2akLH2MbNqGOG5wghpbDC1YHanqeaWqlqCsK79dL5YrUrnukbYjm0qSq3EeElvvIW0LO7Fcxj9k9xQ-n51efjj3B1YFX2No1voqNjqgBQ8zQ0NTqjIoM82LsKCKahVgsqyYlS4qN8Mhk3BtdJGpMDaqZJlmz-CgXtbmBZAyk7II0pJqKrmKMLRRaVnSogziUhdB5EG4lbDQA-S4Zb74JtzVN0tFrxWBWhFOK4J5cLT7zfcecOOvs0-s4nYzLVi2e4EmJAYTEv8yIQ_eotr3_uN8fCHsOwtQmOD3NqEHh1urEMM2bwTNKJ5hCaa4HrzZDeMGtbcusjbLtZsTY1iOca0Hz3sj2n2K4ZpizOM9SPfMa28t-yN1NXcg4JYhC71V4sH7rSX-WtefBfbyfwjsFdyndiM5XpxDOGhXa_Ma7upNWzWrEdxOZol7piO4c3I6yacjtztHtrA2x2cefcWR_OOn_OonshU6wg
linkProvider Directory of Open Access Journals
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwED-NDgQvfH8EBhgETyNa4jhfDwiVj6nVuqqaBuqegu04NBJNR5N2yj_F38jZSTuVib3tgdfYSezkd-c7--5-AG8486OAp8z2vYDZLFTSjlLJbYeb4jIsDEwW_7dBOBxG43E82oLfq1wYHVa50olGUaczqffI92hMES4hehMfTn_ZmjVKn66uKDQaWByo-gxdtvJ9_zP-37eU7n85_tSzW1YBW6JpUtkiUNKhKXNjRV2ViczJYslSN6WCSuGgsyi80KM-Ti7GJhUyqWQaCzdQIvNi6eFzr8E202DvwPaofzg6We_q6HrrEWNtdo7jRXslM7oIl0KbofXu297GCmiIAnBdm-gwzIs27sVQzb_Oa80yuH_nf_uAd-F2a3CTbiMh92BLFffhRkPBWT-A_EiVJh-NdIfH4yN3l0xrlDeheXZ4WZXEkKgThPa0zVWrSV5McpFXBEGZ29ViOpuT3KTZVDVZ5pycdEcu0YExXOf6E036fMbrh_D1Sub5CDrFrFBPgGQx56kTZVRSzoSPNqCIsoymmRNkMnV8C9wVJBLZ1mbXFCE_ExMj4EVJA6MEYZQYGCWeBbvre06byiSX9v6okbbuqauKmwuz-Y-kVVKJLxXV9d80iQATjhSuK3TFfpykkmi6WvAacbrxjF53kOhrupJjiO9buhbsrPCXtPqwTM7BZ8GrdTNqMn08xQs1W5g-Afov6ABY8LhB_fpVHo4piEO8O9qQh42xbLYU-cRUS9dUYrishxa8W4nO-bj-_cGeXj6Nl3Czd3w4SAb94cEzuEW1fBuaoB3oVPOFeg7X5bLKy_mLVkUQ-H7VQvUHXtalSw
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKeYgL70eggEFwKtYmjvM6ILRQVq26Wq2qghYuxnYcNhKbLZvsVvlr_DrGTrLVUtFbD1xjJ7GTb8Yz9sx8CL0WLIhDkTIS-CEjLNKKxKkSxBW2uAyLQpvF_2UYjUbxZJKMt9DvLhfGhFV2OtEq6nSuzB55jyYU4BKBN9HL2rCI8d7g_ckvYhikzElrR6fRQORQ16fgvpXvDvbgX7-hdPDp-OM-aRkGiAIzpSIy1MqlKfMSTT2dyczNEsVSL6WSKumC4yj9yKcBTDSBJh0xpVWaSC_UMvMT5cNzr6CrEfiYJpxwHHxb7--YyusxY22ejuvHvZJZrQSLImFgxwfE31gLLWUArHBTE5B53to9H7T518mtXRAHt__nT3kH3WrNcNxv5OYu2tLFPXS9Ieas76P8SJc2Sw33R8eTI28Xz2qQQmnYd0RZldhSq2MA_KzNYKtxXkxzmVcYoJqTajmbL3Buk2-qGq9ygb_2xx424TLCVADAhgr6VNQP0OdLmedDtF3MC_0Y4SwRInXjjCoqmAzAMpRxltE0c8NMpW7gIK-DB1dtxXZDHPKT28gBP-YNpDhAiltIcd9Bu-t7Tpp6JRf2_mBQt-5pao3bC_PFD96qLh4oTU1VOEMtwKSrpOdJU8cfJqkVGLQOegWY3XjGfn_IzTVT3zGC9608B-10WOStliz5GRAd9HLdDPrNHFqJQs-Xtk8IXg24BQ561EjA-lU-jClMIrg73pCNjbFsthT51NZQNwRjsNhHDnrbidHZuP79wZ5cPI0X6AZIEh8ejA6fopvUiLrlDtpB29ViqZ-ha2pV5eXiudUVGH2_bIn6A47_rK4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Residual+ANTXR1%2B+myofibroblasts+after+chemotherapy+inhibit+anti-tumor+immunity+via+YAP1+signaling+pathway&rft.jtitle=Nature+communications&rft.au=Monika+Licaj&rft.au=Rana+Mhaidly&rft.au=Yann+Kieffer&rft.au=Hugo+Croizer&rft.date=2024-02-12&rft.pub=Nature+Portfolio&rft.eissn=2041-1723&rft.volume=15&rft.issue=1&rft.spage=1&rft.epage=27&rft_id=info:doi/10.1038%2Fs41467-024-45595-3&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_5ce2555834964b0cb11b2617325ec643
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon